Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?


That's one. Then there's... well, actually, that's it. J&J's acquisition of Actelion is the only truly big biotech buyout year to date, unless you also want to include Japanese drugmaker Takeda 's $5.2 billion deal to buy Ariad in the first quarter.



from Biotech News